|
|
Yun-Hong Noh
Commissioner/Korea Food and Drug Administration
B.A. in Russian language, Hankuk University of Foreign Studies (‘83)
M.Sc. (‘93) and Ph.D. Candidate (‘98) in health economics, University of York, United Kingdom
2010.4 ~ present Commissioner of the Korea Food and Drug Administration
2008.3 ~ 2010.3 Secretary to the President for Health and Welfare, Office of the President
2007.3 ~ 2008.3 Director General for Population and Child Policy, Ministry of Health and Welfare
2005.9 ~ 2007.3 Health Policy Bureau Chief, Healthcare Policy Headquarters of the Ministry of Health and Welfare
2004.12 ~ 2005.9 Speaker, Ministry of Health and Welfare
1999.6 ~ 2004.12 Administrative Officer for Health and Welfare, Office of the President
Secretary to the Minister of Health and Welfare
Director for Division of General Affairs, Ministry of Health and Welfare
1996.12 ~ 1998.12 Seconded to Nuffield Institute for Health and to Leeds Health Authority, United Kingdom
1984.4 ~ 1999.6 Ministry of Education, Ministry of Health and Social Policy (Division of Pension System, Division of System for Persons with Disabilities)
1983.12 Passed the 27th National Public Administration Examination | |
|
|
Neil Almstead
Senior Vice President/PTC Therapeutics
Neil Almstead, Ph.D. joined PTC in 2000, and is responsible for PTC's efforts in research, non-clinical development and manufacturing. Under Dr. Almstead's direction, the research and development team has identified and progressed several clinical candidates for oncology and genetic disorders that are currently in advanced stages of clinical development. Ataluren, PTC's most advanced clinical candidate, is focused on the treatment of multiple genetic disorders including duchenne muscular dystrophy and cystic fibrosis. Dr. Almstead joined PTC from Procter & Gamble (P&G) where he was directly involved in the areas of inflammatory diseases and oncology. At P&G he was project leader for both the Matrix Metalloproteinase and Map kinase inhibitor projects. Dr. Almstead has coauthored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders, oncology and inflammatory diseases. After receiving his Ph.D. in Organic Chemistry from the University of Illinois at Urbana-Champaign under the direction of Professor Scott Denmark, Dr. Almstead was a postdoctoral associate at the University of Basel in Switzerland with Professor Bernd Giese. | |
|
|
Bruce E. Maryanoff, Ph.D.
Professor/The Scripps Research Institute
Bruce Maryanoff has been active as a medicinal and organic chemist. He invented TOPAMAX topiramate, a unique sugar sulfamate drug, marketed worldwide for treating epilepsy and migraine, with annual sales >$2 billion. He is an internationally renownd expert in drug design and discovery, esp. the application of protein structure-based drug design. Since 1991 he pursued cardiovascular therapeutics, while seeking drugs for pulmonary inflammation, metabolic disorders, and epilepsy. In the past 15 years, his drug research has dealt with structure-based drug design; peptides/peptidomimetics; enzymes inhibitors, esp. serine proteases/kinases; integrin antagonists; ligands for G-protein-coupled receptors. His efforts led to many new chemical entities entering preclinical development, with 13 advancing into human clinical trials. He made seminal contributions to understanding stereochemistry and mechanism of the Wittig reaction; devised novel peptides that self-assemble to mimic native collagen. Maryanoff is an author on 270 scientific publications, including books (Editor), book chapters, review articles. He is an inventor on 100 U.S. patents (issued/pending), presented >150 invited lectures, mentored 11 postdocs. He is Assoc. Editor of ACS Med. Chem. Lett.; organized/edited a special issue of J. Med. Chem. to honor Dr. Paul Janssen; has served on editorial advisory boards for journals and research grant committees. Maryanoff received two American Chemical Society national awards, and the prestigious Smissman Award from the Med. Chem. Division of the ACS; was inducted into the ACS Medicinal Chemistry Hall of Fame in 2008; was elected Fellow of the ACS, Amer. Assoc. for the Advancement of Science, and Royal Society of Chemistry. He retired from Johnson & Johnson in Jan 2010, after 36 years of service, and is now affiliated with The Scripps Research Institute (La Jolla, CA); Pennsylvania Drug Discovery Institute (Doylestown, PA); Institute for Hepatitis and Virus Research. | |
|
|
Yuan-Hua Ding
Senior Director/Pfizer External R&D Innovation (ERDI)
Dr. Yuan-Hua Ding is a Senior Director and Head of Pfizer External R&D Innovation (ERDI) – Asia, Pfizer Worldwide Research & Developmen. He is also a member of the ERDI senior leadership team. In this capacity, he partners with colleagues in ERDI, Pfizer Business Development Group and Pfizer Asia Research to evaluate academic & biotech research capabilities in Asia, seek opportunities to incubate early biotech companies, build and manage a research network of academic institutes, biotech companies and Contracted Research Organizations (CROs). He liaises with therapeutic area and technology research unit leaderships in accessing the sciences, technologies and products needed to support Pfizer mission in Asia. Prior to his current role, Dr. Ding hold a variety of positions in the Pfizer R&D division, including Head of Asia External Science and Technology, Head of Structural Biology at the Research Technology Center (RTC) in Cambridge, MA, Associate Research Fellow and Senior Research Scientist. Dr. Ding received a bachelor’s degree in Electronic Engineering from Peking University in 1987 and a master’s degree in Biophysics from Tsinghua University in 1990. In 1996, after completed his doctoral studies in Biochemistry at the University of Pittsburgh, he moved to Harvard University to be a postdoctoral fellow. | |
|
|
Sung-Joo Lee
R&D Managing Director/Sanofi-Aventis Korea
Stanford University, Postdoctoral Fellow
University of California, Berkeley/ Ph.D. in Biophysics
Korea R&D Representative, Regional Growth, Asia Pacific R&D, sanofi-aventis R&D
LG Life Sciences, Director, R&D Collaboration, Strategic Planning Team / Modeling Team, Drug Design Laboratory | |
|
|
Kyung Sun
Director of Bureau of HT R&D Planning and Budget Management/Korea Health Industry Development Institute
1975-1981 Korea University Medical College (BMS)
1982-1984 Korea University Graduate School (MMS)
1982-1990 Korea University Graduate School (PhD)
2004-2007 Korea University Business School (MBA)
(Past)
1981 Medial Doctor
1986 National Board Certified for Thoracic and Cardiovascular Surgery
2009 National Board Certified for Intensive Care Medicine
Director of External Affairs of Korea University Medical Center
Director of Business Development of Korea University Medical Center
Korea University Vice-president for Medical Planning and Budget
Advisory Board Member of Presidential Council for Medical Industrialization
Member of Medical Technology Policy Evaluation Committee
Co-chair of HT Forum of Health and welfare Ministry, Steering Committee Member of National Science and Technology Commission
(Current)
Advisory Board Member of Korea FDA
Advisory Board Member of National Statistics Office
Member of National Academy of Medicine of Korea
Member of Bio and Welfare Committee of National Science and Technology Commission
Board Member of International Federation for Artificial Organs
Professor of Thoracic and Cardiovascular Surgery, Korea University Medical School
Director of Korea Artificial Organ Center
Director of Bureau of HT R&D Planning and Budget Management, Korea Health Industry Development Institute | |
|
|
Kyu-Yang Yi
Principal Research Scientist/Korea Research Institute of Chemical Technology
1978 - 1982 Seoul National University, B.S. Chemistry & Education
1982 - 1984 Korea Advanced Institute of Science and Technology, M.S. Organic Chemistry
1984 - 1987 Korea Advanced Institute of Science and Technology, Ph.D. Organic Chemistry
1991 - 1992 Harvard University, Post-Doc. Organic Chemistry
1987 - 1995 Senior Research Scientist, Korea Research Institute of Chemical Technology(KRICT)
1995 - Principal Research Scientist, KRICT
2000 - 2007 Group Leader, Cardiovascular Disease Research, KRICT
2008 - 2011 Director, Metabolic Syndrome Therapeutics Research Center, KRICT
2010 - 2010 Vice President, The Korean Chemical Society
2001 - 2002 Adjunct Professor, Dept. of Chemistry, Chungnam National University
2009 - Adjunct Professor, Dept. of Medicinal and Pharmaceutical Chemistry, University of Science & Technology
Discovery of Drug Candidate for Glaucoma
Discovery of Drug Candidate for Ischemic Diseases
Discovery of Drug Candidate for Macular Degeneration | |
|
|
Se-Woong Oh
Team Leader, Project Planning Team, Central Research Institute/JW Pharmaceutical Corp.
1993 Veterinary Medicine, Collage of Vet. Med., Seoul Nat’l University
1995 M.S. in Veterinary Pathology, Seoul Nat’l University
2008 Ph.D. in Veterinary Pathology, Seoul Nat’l University
1995~1998: Research Scientist, Central Research Institute, Choongwae Pharma Corp.
1998~2004: Senior Scientist, Central Research Institute, Choongwae Pharma Corp.
1999~2000: Visiting scientist, Allergy and Infectious Disease, Department of Medicine, University of Washington, WA, U.S.A.
2005~present: Principal Scientist, Central Research Institute, JW Pharmaceutical Corp. | |
|
|
Chong-Hwan Chang
President of Center/Advance Drug Development
1973 B.S. Seoul National University
1975 M.S Seoul National University
1982 PhD. University of Pittsburgh
1982- 1991 Biophysicist, Argonne National Laboratory
1985- 1991 Adjunct Assistant Professor, College of Pharmacy, The University of Illinois at Chicago
1991- 2001 DuPont Pharmaceutical Company, Director
2001- 2004 BMS, Structural Biology and Molecular Design, director
2006- 2009 Member of the committee chaired by prime minister on National policy of life science
2005- 2010 Green Cross Corp, CTO, Executive Vice President
2011- President of Center for Advance Drug Development
One drug in market $800M/year sale, Sustiva (for AIDS).
Numerous others in development.
More than 70 publications in a review journal. | |
|
|
Eun-Chul Huh
Head, Planning & Administration/Mogam Biotech Research Institute
1994 Bachelor of Science, Food Science, Seoul National University
1998 Master of Science, Biochemical Engineering, Seoul National University
2004 Doctor of Philosophy, Food Science & Technology, Cornell University, USA
2004 – 2005 Head, Planning & Administration, Mogam Biotech Research Institute
2006 – 2007 Managing Director, R&D Strategic Planning, Green Cross Corp.
2008 – 2009 Senior Managing Director, R&D Strategic Planning, Green Cross Corp.
2009 – present Executive Vice President, Research & Development, Green Cross Corp. | |
|
|
Vince Rubino
Global Team Leader/Korea Institute of Toxicology
Vince Rubino has performed roles in engineering, validation and QA at Bayer Healthcare Pharmaceuticals, and is currently a Society of Quality Assurance (SQA) registered professional in Good Laboratory Practices (GLPs).
Vince has a degree in Bioengineering from UC Berkeley and is currently Global Team Leader for Korea Institute of Toxicology. Vince has also served as a Korean delegate to the International Standards Organization (ISO) Nanotechnologies group. | |
|
|
Sang-Goo Shin, M.D., Ph.D
President/Korea National Enterprise for Clinical Trials
< Affiliation &Title >
- Professor of Clinical Pharmacology / Pharmacology, Seoul National University (SNU) College of Medicine
-Director, Clinical Research Institute, Seoul National University Hospital
-Leader, Korean Pharmacogenomic Research Network, KMHW
1968-1974: Seoul National University College of Medicine, Seoul, Korea: M.D.
1974- 1982: Seoul National University Graduate School, Seoul, Korea: Ph.D.
1974 - 1978 Assistant, Department of Pharmacology, SNU College of Medicine
1978 - 1981 Flight Surgeon, Aerospace Medical Institute, Korean Air Force
1981 - 1983 Assistant Professor (Pharmacology), Chungang Univ. College of Medicine
1983 - 1986 Assistant Professor (Pharmacology), SNU College of Medicine
1986 - 1987 Fellowship training in Clinical Pharmacology, Clinical Pharmacology Center, Northwestern Memorial Hospital, Northwestern Univ. College of Medicine, Chicago, U.S.A.
1988 - 1993 Associate Professor, SNU College of Medicine
1997.5 – 1999.4 Associate Dean for Research Affairs, SNU College of Medicine
1993 - Present Professor, SNU College of Medicine
1988 – 2002.5 Director, Clinical Pharmacology Unit / SNUH
1996 – 2005. 11 Director, Clinical Trial Center / SNUH
2003.7 – Present Leader, Korea Pharmacogenomic Research Network
2005.6 – Present Director, KMA Center for Drug Information & Evaluation
2005. 11. 15 – Present Director, Clinical Research Institute/Seoul National University Hospital | |
|
